General discussion, page-16889

Thanks for sharing this.

Many long term holders have previously explained why no big pharma will be buying up IHL at current stage due to many reasons such as ongoing trials and various risk.

However, as Jmiller pointed out, now there is a big pharma willing to acquire pre clinical pipeline of a potential competitor.

Can someone please enlighten me the logic/reasons behind this?